^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SLITRK6-targeted antibody-drug conjugate

    Related drugs:
    5ms
    Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review. (PubMed, Bladder Cancer)
    In addition to enfortumab vedotin and sacituzumab govitecan, various HER2-targeted antibody drug conjugates and ADC-anti-PD-1 combination regimens have demonstrated efficacy in clinical trials and are poised for clinical advancement.
    Review • Journal • Combination therapy • Metastases
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4) • SLITRK6 (SLIT And NTRK Like Family Member 6)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)